T cell design for therapy in autoimmune demyelinating disease

Journal of Neuroimmunology

Volumn 107, Issue 2, 2000, Pages 226-232

  Tuohy, Vincent K ^a   Mathisen, Peter M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmunity; Encephalomyelitis; Gene therapy; Multiple sclerosis; PDGF; T cell

Indexed keywords

ANTIBIOTIC G 418; ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; NEOMYCIN; PLATELET DERIVED GROWTH FACTOR; REAGENT; VIRUS VECTOR;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CONFERENCE PAPER; DEMYELINATING DISEASE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; TRANSGENES;

EID: 0034710381     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00234-4     Document Type: Conference Paper

References (38)

1. Armstrong R.C., Harvath L., Dubois-Dalcq M.E. Type-1 astrocytes and oligodendrocytes - type 2 astrocyte glial progenitors migrate toward distinct molecules. J. Neurosci. Res. 27:1990;400-407.
2. Barres B.A., Hart I.K., Coles H.S.R., Burne J.F., Voyvodic J.T., Richardson W.D., Raff M.C. Cell death and control of cell survival in the oligodendrocyte lineage. Cell. 70:1992;31-46.
3. Barres B.A., Schmid R., Sendnter M., Raff M.C. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development. 118:1993;283-295.
4. Bohl D., Naffakh N., Heard J.M. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat. Med. 3:1997;299-305.
5. Burcin M.M., Schiedner G., Kochanek S., Tsai S.Y., O'Malley B.W. Adenovirus-mediated regulable target gene expression in vitro. Proc. Natl. Acad. Sci. USA. 96:1999;355-360.
6. Deng H., Lin Q., Khavari P.A. Sustainable cutaneous gene delivery. Nat. Biotech. 15:1997;1388-1391.
7. Emery D.W., Stamatoyannopoulos G. Stem cell gene therapy for the β-chain hemoglobinopathies: problems and progress. Ann. New York Acad. Sci. 87:1999;94-108.
8. Gossen M. Transcriptional activation by tetracyclines in mammalian cells. Science. 268:1995;1766-1769.
9. Kamogawa Y., Minasi L., Carding S.R., Bottomly K., Flavell R.A. the relationship of IL-4- and IFNγ-producing T cells studied by lineage ablation of IL-4-producing cells. Cell. 75:1993;985-995.
10. Karpen G.H. Position-effect variegation and the new biology of heterochromatin. Curr. Opin. Genet. Dev. 4:1994;281-291.
11. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
12. Mathisen P.M., Tuohy V.K. Gene therapy in the treatment of autoimmune disease. Immunol. Today. 19:1998;103-105.
13. Mathisen P.M., Yu M., Johnson J.M., Drazba J.A., Tuohy V.K. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med. 186:1997;159-164.
14. Mathisen P.M., Yu M., Yin L., Johnson J.M., Kawczak J.A., Nishiyama A., Tuohy V.K. Th2 T cells expressing transgene PDGF-A serve as vectors for gene therapy in autoimmune demyelinating disease. J. Autoimmun. 13:1999;31-38.
15. McAllister B.S., Leeb-Lundberg F., Olson M.S. Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts. Am. J. Physiol. 265:1993;C477-C484.
16. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:1995;75-85.
17. Morgan R.A., Anderson F.W. Human gene therapy. Annu. Rev. Biochem. 62:1993;191-217.
18. Mulligan R.C. The basic science of gene therapy. Science. 260:1993;926-932.
19. Neff T., Shotkoski F., Stamatoyannopoulos G. Stem cell gene therapy, position effects and chromatin insulators. Stem Cells. 15:(Suppl. 1):1997;265-271.
20. Nishiyama A., Lin X.-H., Giese N., Heldin C.-H., Stallcup W.B. Interaction between NG2 proteoglycan and PDGFα-receptor on O2A progenitor cells is required for optimal response to PDGF. J. Neurosci. Res. 43:1996;315-330.
21. Novak T.J., White P.M., Rothenberg E.V. Regulatory anatomy of the murine interleukin-2 gene. Nucleic Acids Res. 18:1990;4523-4533.
22. Pringle N., Collarini E.J., Mosley M.J., Heldin C.-H., Westermark B., Richardson W.D. PDGF A chain homodimers drive proliferation of bipotential (O2A) glial progenitors cells in the developing rat optic nerve. EMBO J. 8:1989;1049-1056.
23. Raff M.C., Miller R.H., Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 303:1983;390-396.
24. Raff M.C., Abney E.R., Fok-Seang J. Reconstruction of a developmental clock in vitro: a critical role for astrocytes in the timing of oligodendrocyte differentiation. Cell. 42:1985;61-69.
25. Richardson W.D., Pringle N., Mosley M.J., Westermark B., Dubois-Dalq M. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell. 53:1988;309-319.
26. Rivella S., Sadelain M. Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin. Hematol. 35:1998;112-125.
27. Rivera V.M., Clackson T., Natesan S., Pollock R., Amara J.F., Keenan T., Magari S.R., Phillips T., Courage N.L., Cerasoli F. Jr., Holt D.A., Gilman M. A humanized system for pharmacologic control of gene expression. Nat. Med. 2:1996;1028-1032.
28. Robbins P.D., Evans C.H. Prospects for treating autoimmune and inflammatory diseases by gene therapy. Gene Ther. 3:1996;187-189.
29. Robbins P.B., Skelton D.C., Yu X.-J., Halene S., Leonard E.L., Kohn D.B. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Natl. Acad. Sci. USA. 95:1998;10182-10187.
30. Schmidt-Wolf G.D., Schmidt-Wolf I.G.H. Cytokines and gene therapy. Immunol. Today. 16:1995;173-175.
31. Tuohy V.K., Mathisen P.M. T cell design: optimizing the therapeutic potential of autoreactive T cells by genetic modification. Res. Immunol. 149:1998;834-842.
32. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Johnson J.M., Mathisen P.M., Weinstock-Guttman B., Kinkel R.P. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 164:1998;93-100.
33. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Kinkel R.P. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalo-myelitis and multiple sclerosis. J. Exp. Med. 189:1999;1033-1042.
34. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Kinkel R.P. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J. Autoimmun. 13:1999;11-20.
35. Vanderlugt C.J., Miller S.D. Epitope spreading. Curr. Opin. Immunol. 8:1996;831-836.
36. Wilson J.M. Vectors - shuttle vehicles for gene therapy. Clin. Exp. Immunol. 107:(Suppl. 1):1997;31-32.
37. Ye X., Rivera V.M., Zoltick P., Cerasoli F. Jr., Schnell M.A., Guang-ping G., Hughes J.V., Gilman M., Wilson J.M. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 283:1999;88-91.
38. Yu M., Johnson J.M., Tuohy V.K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183:1996;1777-1788.